

Anja Geerts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3457832/publications.pdf>

Version: 2024-02-01

53
papers

2,157
citations

331642

21
h-index

243610

44
g-index

55
all docs

55
docs citations

55
times ranked

3311
citing authors

#	ARTICLE	IF	CITATIONS
1	Glycomics-based serum markers as reliable tool for assessment of viral response after treatment with direct-acting antiviral drugs in hepatitis C virus infection. <i>Acta Clinica Belgica</i> , 2023, 78, 96-102.	1.2	2
2	Maternal and Perinatal Risk Factors for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 740-755.	4.4	19
3	Safety and efficacy of the JAK-inhibitor tofacitinib in patients with primary sclerosing cholangitis: a multicentre, retrospective study. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.5	1
4	⁹⁰ Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial. <i>Radiology</i> , 2022, 303, 699-710.	7.3	74
5	Health status of patients with autoimmune hepatitis is not affected by the SARS-CoV-2 outbreak in Flanders, Belgium. <i>Journal of Hepatology</i> , 2021, 74, 240-241.	3.7	12
6	NOX1 inhibition attenuates the development of a pro-tumorigenic environment in experimental hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 40.	8.6	13
7	Characterization of the inflammatory microenvironment and hepatic macrophage subsets in experimental hepatocellular carcinoma models. <i>Oncotarget</i> , 2021, 12, 562-577.	1.8	11
8	Metallothioneins alter macrophage phenotype and represent novel therapeutic targets for acetaminophen-induced liver injury. <i>Journal of Leukocyte Biology</i> , 2021, 111, 123-133.	3.3	8
9	Bariatric surgery and the liver—Mechanisms, benefits, and risks. <i>Obesity Reviews</i> , 2021, 22, e13294.	6.5	24
10	The utility of biomarkers in prognosis assessment of patients with acute liver failure. <i>Hepatology Research</i> , 2021, 51, 750-757.	3.4	5
11	Reply to “Perinatal risk factors for pediatric non-alcoholic fatty liver disease: Impact of inborn errors of metabolism”. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	4.4	0
12	The neuroglivascular unit in hepatic encephalopathy. <i>JHEP Reports</i> , 2021, 3, 100352.	4.9	22
13	Serum Glycomics on Postoperative Day 7 Are Associated With Graft Loss Within 3 Months After Liver Transplantation Regardless of Early Allograft Dysfunction. <i>Transplantation</i> , 2021, 105, 2404-2410.	1.0	3
14	Combination of sivelestat and N-acetylcysteine alleviates the inflammatory response and exceeds standard treatment for acetaminophen-induced liver injury. <i>Journal of Leukocyte Biology</i> , 2020, 107, 341-355.	3.3	21
15	Up to 50% of portal vein thrombosis remains undiagnosed until liver transplantation. <i>Clinical Transplantation</i> , 2020, 34, e14107.	1.6	6
16	Bariatric Surgery Patients Are at Risk for Alcoholic Liver Disease with Need for Liver Transplantation. <i>Obesity Surgery</i> , 2020, 30, 4659-4664.	2.1	15
17	Vasomodulators and Liver Transplantation for Portopulmonary Hypertension: Evidence From a Systematic Review and Meta-Analysis. <i>Hepatology</i> , 2020, 72, 1701-1716.	7.3	27
18	Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. <i>Journal of Hepatology</i> , 2020, 73, 757-770.	3.7	154

#	ARTICLE	IF	CITATIONS
19	Myeloid-specific IRE1 α deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model. <i>Metabolism: Clinical and Experimental</i> , 2020, 107, 154220.	3.4	19
20	Charting Extracellular Transcriptomes in The Human Biofluid RNA Atlas. <i>Cell Reports</i> , 2020, 33, 108552.	6.4	50
21	Effect of isoform-specific HIF-1 \pm and HIF-2 \pm antisense oligonucleotides on tumorigenesis, inflammation and fibrosis in a hepatocellular carcinoma mouse model. <i>Oncotarget</i> , 2020, 11, 4504-4520.	1.8	13
22	Histologically proven hepatic steatosis associates with lower testosterone levels in men with obesity. <i>Asian Journal of Andrology</i> , 2020, 22, 252.	1.6	13
23	Outcome of liver transplantation for hepatopulmonary syndrome: a Eurotransplant experience. <i>European Respiratory Journal</i> , 2019, 53, 1801096.	6.7	16
24	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	13.7	818
25	Why Pulse Oximetry Is Inaccurate in Liver Cirrhosis: Ancient Knowledge. <i>Hepatology</i> , 2019, 69, 462-463.	7.3	7
26	Secondary Adrenal Insufficiency after Treatment with Budesonide for Autoimmune Hepatitis. <i>Case Reports in Gastroenterology</i> , 2019, 12, 597-601.	0.6	7
27	Angiopoietin β Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 69, 1087-1104.	7.3	82
28	Insulin resistance associates with hepatic lobular inflammation in subjects with obesity. <i>Endocrine Connections</i> , 2019, 8, 1294-1301.	1.9	7
29	Severe Hepatic and Pulmonary Involvement in Rendu-Osler-Weber Syndrome. <i>Case Reports in Gastroenterology</i> , 2018, 12, 13-18.	0.6	1
30	Glycome Patterns of Perfusate in Livers Before Transplantation Associate With Primary Nonfunction. <i>Gastroenterology</i> , 2018, 154, 1361-1368.	1.3	13
31	Maternal liver transplant: Another cause of discordant fetal sex determination using cell-free DNA. <i>Prenatal Diagnosis</i> , 2018, 38, 148-150.	2.3	20
32	Clinical burden of hepatitis E virus infection in a tertiary care center in Flanders, Belgium. <i>Journal of Clinical Virology</i> , 2018, 103, 8-11.	3.1	5
33	Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in mice. <i>Hepatology</i> , 2018, 68, 634-651.	7.3	39
34	Refractory subacute steatohepatitis after biliopancreatic diversion. <i>Hepatology</i> , 2017, 66, 289-291.	7.3	12
35	Hepatitis E virus serology and PCR: does the methodology matter?. <i>Archives of Virology</i> , 2017, 162, 2625-2632.	2.1	15
36	A Glycomics-Based Test Predicts the Development of Hepatocellular Carcinoma in Cirrhosis. <i>Clinical Cancer Research</i> , 2017, 23, 2750-2758.	7.0	31

#	ARTICLE	IF	CITATIONS
37	Non-alcoholic steatohepatitis induces transient changes within the liver macrophage pool. Cellular Immunology, 2017, 322, 74-83.	3.0	81
38	Combination of tauroursodeoxycholic acid and N-acetylcysteine exceeds standard treatment for acetaminophen intoxication. Liver International, 2017, 37, 748-756.	3.9	24
39	Modulation of the Unfolded Protein Response by Tauroursodeoxycholic Acid Counteracts Apoptotic Cell Death and Fibrosis in a Mouse Model for Secondary Biliary Liver Fibrosis. International Journal of Molecular Sciences, 2017, 18, 214.	4.1	24
40	Heads or Tails: Genotyping of Hepatitis C Virus Concerning the 2k/1b Circulating Recombinant Form. International Journal of Molecular Sciences, 2016, 17, 1384.	4.1	10
41	Longitudinal Transient Elastography Measurements Used in Follow-up for Patients with Cystic Fibrosis. Ultrasound in Medicine and Biology, 2016, 42, 848-854.	1.5	25
42	Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease. Cellular and Molecular Life Sciences, 2016, 73, 3419-3431.	5.4	50
43	Targeting the angio-proteostasis network: Combining the forces against cancer. , 2016, 167, 1-12.		10
44	Placental growth factor inhibition modulates the interplay between hypoxia and unfolded protein response in hepatocellular carcinoma. BMC Cancer, 2016, 16, 9.	2.6	26
45	The role of macrophages in obesity-driven chronic liver disease. Journal of Leukocyte Biology, 2016, 99, 693-698.	3.3	34
46	Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity. Obesity, 2016, 24, 2544-2552.	3.0	23
47	Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma. Oncotarget, 2016, 7, 34988-35000.	1.8	22
48	Quality of life after liver transplantation: State of the art. World Journal of Hepatology, 2016, 8, 749.	2.0	50
49	Time-Dependent Effect of Hypoxia on Tumor Progression and Liver Progenitor Cell Markers in Primary Liver Tumors. PLoS ONE, 2015, 10, e0119555.	2.5	12
50	Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment. Liver International, 2015, 35, 1646-1660.	3.9	81
51	Modulation of the unfolded protein response impedes tumor cell adaptation to proteotoxic stress: a PERK for hepatocellular carcinoma therapy. Hepatology International, 2015, 9, 93-104.	4.2	58
52	Tauroursodeoxycholic acid dampens oncogenic apoptosis induced by endoplasmic reticulum stress during hepatocarcinogen exposure. Oncotarget, 2015, 6, 28011-28025.	1.8	36
53	Evaluation of the value of serum glycomics (GlycoCirrhoTest) for risk prediction of hepatocellular carcinoma in compensated cirrhosis.. Journal of Clinical Oncology, 2015, 33, 4079-4079.	1.6	0